EGFR and cancer: Our data show that left-sided CRC cancer cells exhibited significantly stronger EGFR signaling, VEGF signaling, and ErbB signaling than right-sided CRC cells (Figure 8C), which is consistent with our clinical findings that left-sided CRC is more sensitive to monoclonal antibodies against EGFR, VEGF and ErbB.